Research programme: antibacterials - Abgentis
Alternative Names: GYR 12Latest Information Update: 14 Sep 2023
Price :
$50 *
At a glance
- Originator Abgentis
- Class Antibacterials; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 14 Sep 2023 Discontinued - Preclinical for Bacterial infections in United Kingdom (IV)
- 14 Sep 2023 Discontinued - Preclinical for Bacterial infections in United Kingdom (PO)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Bacterial-infections in United Kingdom (IV)